Phase I/II Trial of Ruxolitinib in combination with Trastuzumab in Metastatic Her2 positive breast cancer

ID Number 14-1418

Principal Investigator(s)
Amy Tiersten

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to examine the safety and effectiveness of ruxolitinib in combination with trastuzumab in the treatment of HER2 positive metastatic breast cancer.  HER2 positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promoted the growth of cancer cells.

Ruxolitinib (Jakafi) is an FDA approved treatment of myelofibrosis (a disease of the bone marrow), but it's safety and effectiveness in breast cancer patients is not known.  Ruxolitinib is being used in an investigational manner in this research study.  Ruxolitinib is a type of therapy that inhibits the JAK/STAT growth pathway.  Research in the lab shows that this pathway is important for HER2 positive breast cancers to grow.  This drug is targeted to stop that pathway.

Trastuzumab (Herceptin) is an FDA approved treatment for HER2 positive breast cancer.  The safety and efficacy of both treatments given in combination is not known.

Contact Information
Deborah Lehrer
(212) 824-7309

Recruiting Patients: Yes